• Explore /
  • Poster
  • / Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC).

Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC).

Abstract Video & Slides Poster

Authors

null

Neal D. Shore

Carolina Urologic Research Center, Myrtle Beach, SC

Neal D. Shore , Mark A. Preston , Justin R Gregg , Simpa Samuel Salami , Ashley Ross , Amanda Bruno , Shankar Srinivasan , Niculae Constantinovici , Jorge A. Ortiz , Patrick Adorjan , Frank Verholen , Rana R. McKay

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Other

Clinical Trial Registration Number

NCT05059236

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS297)

DOI

10.1200/JCO.2023.41.6_suppl.TPS297

Abstract #

TPS297

Poster Bd #

Q19

Abstract Disclosures

Similar Posters

First Author: Neal D. Shore

First Author: Neal D. Shore

First Author: Lauren Christine Harshman

First Author: Andrew J. Armstrong